ストックスクリーナーアプリを入手
49.45
1.57%
-0.79
アフターアワーズ：
49.45
前日終値:
$50.24
開ける：
$50.15
24時間の取引高:
6.01M
Relative Volume:
4.27
時価総額：
$3.62B
収益：
-
当期純損益:
$-98.78M
株価収益率:
-29.72
EPS:
-1.6638
ネットキャッシュフロー:
$-65.60M
1週間 パフォーマンス:
-8.97%
1か月 パフォーマンス:
-17.68%
6か月 パフォーマンス:
+81.47%
1年 パフォーマンス:
+148.18%
1日の値動き範囲:
$49.19
$51.20
1週間の範囲:
$48.42
$55.83
52週間の値動き範囲:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Compare ELVN vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
49.45 | 3.98B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire
Enliven will present leukemia drug data twice at a Houston meeting - Stock Titan
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (ELVN) Pulls Back 1.44% to $58.56 as Support HoldsInsider Sentiment - vinanet.vn
Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
ELVN Q2 2026 Earnings: Wider Net Loss and Negative Surprise Weigh on SharesEarnings Surprise Report - vinanet.vn
How (ELVN) Movements Inform Risk Allocation Models - Stock Traders Daily
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Enliven Therapeutics (ELVN) and AMN Healthcare Services (AMN) - theglobeandmail.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Enliven Therapeutics (ELVN) and Geron (GERN) - The Globe and Mail
We're Interested To See How Enliven Therapeutics (NASDAQ:ELVN) Uses Its Cash Hoard To Grow - Moomoo
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
大文字化:
|
ボリューム (24 時間):